Saturday, October 31, 2026

Businesses Losing on Lack of Women in Leadership Roles

Ruchi Gupta

January 17, 2019

Woman in Business at the White House. Photo by: Business Forward.

Research findings have, over the years, shown that an increase of women in leadership roles might be good for business. Even with findings, very few women make up the top echelons of power in most businesses as well as public companies.

According to the UC Davis Study of California Women Business Leaders study, carried out on companies in California, U.S.A, indicates that businesses with at least some women in high positions were doing extremely well compared to those with none. According to the study, 25 firms with the highest percentage of women in leadership roles delivered at least, 74% higher returns, than other companies."

Women and success in business

The longer it takes to absorb more women into high positions, the longer it will take to bridge gender gaps. In return, businesses will continue to lose out given the number of skills as well as experience that most women bring to the table. A research report published by the McKinsey Global Institute indicates that the world could add as much as $12 trillion in the annual gross domestic product on women assuming more leadership roles.

Public companies are yet to reach the threshold of parity when it comes to gender equality in management roles. Men continue to call the shorts as evidenced in some of the biggest companies in the world. This is despite findings showing that a high percentage of women in high positions could translate to excess returns for shareholders.

Need to invest in women

A study conducted by Nordea indicated that corporate companies run by women tend to perform better than the overall market. The study showed that companies with a woman Chief Executive Officer or Chairperson of the board delivered annualized returns of up to 25%, more than double the 11% delivered by MSCI World Index since 2009.

“If you invested in a company with a woman at the helm, you would have outperformed the market,” commented Robert Næss, the portfolio manager at Nordau who designed the study, in a release. “Other studies have also shown that diversity is a positive factor, but not that many have also looked at CEOs or such a large number of companies.”

One of the key barriers to women occupying top positions in management has to do with cultural issues. The perception that women main role is raising kids and not running a business, continue to influence many employers decisions.
Until there is a dramatic shift in traditions as well recognition of women in leadership, many businesses might continue to lag behind.

Tags

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com